Diagnosing diabetes in 2000

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 1, 2000, Pages 31-37

  Peters, Anne L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GLUCOSE BLOOD LEVEL; HISTORY OF MEDICINE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; SCREENING TEST; VASCULAR DISEASE;

EID: 0034007506     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200002000-00005     Document Type: Article

References (58)

1. 1 McCance D, Hanson RL, Charles M-A, et al.: Comparison of tests for glycated haemoglobin and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J 1994, 308:1323-1328.
2. 2 Zimmet P, Whithouse S: The effect of age on glucose tolerance: studies in a Micronesian population with a high prevalence of diabetes. Diabetes 1979, 28:617-623.
3. 3 Gordon T: Glucose tolerance of adults, United States, 1960-1962: diabetes prevalence and results of glucose tolerance test, by age and sex. Vital and Health Statistics, Washington D.C., U.S. Government Printing Office, 1964 (Series 11, No. 2).
4. 4 Hayner NS, Kjelsberg MD, Epstein FH, Francis T: Carbohydrate tolerance and diabetes in a total community, Tecumseh, Michigan. 1. Effects of age, sex, and test conditions on one-hour glucose tolerance in adults. Diabetes 1965, 14:413-423.
5. 5 Valleron AJ, Eschwege E, Papoz E, Rosselin GE: Agreement and discrepancy in the evaluation of normal and diabetic oral glucose tolerance test. Diabetes 1975, 24:585-593.
6. 6 National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28:1039-1057.
7. 7 World Health Organization: World Health Organization Expert Committee on Diabetes Mellitus: Second Report. Geneva, Switzerland: World Health Organization, 1980. Technical report 646.
8. 8 Jarrett RJ, Keen H: Hyperglycaemia and diabetes mellitus. Lancet 1976, 2:1009-1012.
9. 9 Sayegh HA, Jarrett RJ: Oral glucose-tolerance tests and the diagnosis of diabetes: results of a prospective study based on the Whitehall survey. Lancet 1979, 2:431-433.
10. 10 Pettitt DJ, Knowler WC, Lisse JR, Bennett PH: Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians. Lancet 1980, 2:1050-1052.
11. 11 Davidson MB, Peters AL, Schriger DL: An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care 1995, 18:1065-1071. Review of literature on diagnosing diabetes.
12. 12 Expert Committee: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997:20:1183-1197.
13. 13 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 22 (Suppl 1):S5-S19, 1999. Basis for diagnosing diabetes.
14. 14 Olefsky JM, Reaven GM: Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 1974, 23:449-453.
15. 15 Kosaka K, Mizuno Y, Kuzuga T: Reproducibility of the oral glucose tolerance test and the rice-meal test in mild diabetes. Diabetes 1966, 15:901-904.
16. 16 Wilkerson HLC, Butler FK, Francis JOS: The effect of prior carbohydrate intake on the oral glucose tolerance test. Diabetes 1960, 9:386-391.
17. 17 Rushforth NB, Miller M, Bennett PH: Fasting and two-hour post-load glucose levels for the diagnosis of diabetes. Diabetologia 1979, 16:373-379.
18. 18 Melton LJ, Palumbo PJ, Chu C-P: Incidence of diabetes mellitus by clinical type. Diabetes Care 1983, 6:75-86.
19. 19 Stolk RP, Orchard TJ, Grobbee DE: Why use the oral glucose tolerance test? Diabetes Care 1995, 18:1045-1049.
20. 20 Hanson RL, Nelson RG, McCance DR, et al.: Comparison of screening tests for non-insulin-dependent diabetes mellitus. Arch Int Med 1993, 153:2133-2140.
21. 21 Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al.: Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997, 20:785-791.
22. 22 Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care 1998, 21:518-524. Excellent data on diabetes in the United States.
23. 23 Bucala R, Cerami A, Vlassara H: Advanced glycosylation end products in diabetic complications. Diabetes Rev 1995, 3:258-268.
24. 24 Cohen MP, Sharma K, Jin Y, et al.: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. J Clin Invest 1995, 95:2338-2345.
25. 25 Clements RS Jr, Robsion WG Jr, Cohen MP: Antiglycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diabetes Complications 1998, 12:28-33.
26. 26 Nakamura S, Makita Z, Ishikawa S, et al.: Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997, 46:895-899.
27. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995, 44:968-983.
28. 28 Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995, 332:1251-1255.
29. 29 Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 1995, 28:103-117.
30. 30 Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R: Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 1998, 21:116-120.
31. 31 UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:839-855.
32. 1c standardization.
33. 33 American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999, 22(Suppl 1):S32-S41.
34. 34 Davidson MB, Schriger DL, Peters AL, Lorber B: Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA 1999, 281:1203-1210.
35. 35 Peters AL: New criteria for the diagnosis of diabetes and the relationship to macrovascular disease. Preventive Cardiology Spring 1998, X:57-59.
36. 36 Davidoff F: Blood sugar, disease, and nondisease. Ann Intern Med 1997, 127:235-237.
37. 37 Peters AL, Davidson MB, Schriger DL, Hasselblad V, the Meta-analysis Resarch Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels: A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycated hemoglobin levels. JAMA 1996, 276:1246-1252.
38. 38 Modan M, Harris MI: Fasting plasma glucose in screening for NIDDM in the US and Israel. Diabetes Care 1994, 17:436-444.
39. 39 Shaw JE, de Courten M, Boyko EJ, Zimmet PZ: Impact of new diagnostic criteria for diabetes in different populations. Diabetes Care 1999, 22:762-766. Reviews glycemic parameters in a variety of populations.
40. 40 Dinneen SF, Maldonado D, Leibson CL, Klee GG, Li H, Melton LJ, Rizza RA: Effects of changing diagnositc criteria on the risk of developing diabetes. Diabetes Care 1998, 21:1408-1413. Excellent article regarding impact of new criteria on diagnosing diabetes.
41. 41 The DECODE Study Group: Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999, 42:647-654. Aggregate data on the use of fasting glucose levels for diagnosing diabetes.
42. 42 Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-607.
43. 43 Deedwania PC, ed: Proceedings of a symposium: the cardiovascular dysmetabolic syndrome. Am J Med 1998, 105(1A):1S-82S.
44. 44 Meigs JB, Nathan DM, Wilson PWF, Cupples A, Singer DE: Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. Ann Intern Med 1998, 128:524-533. Illustrates risk of insulin resistance at normal glucose levels.
45. 45 Rodriguez BI, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD: Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu heart program. Diabetes Care 1999, 22:1262-1265.
46. 46 Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. Diabetes Care 1999, 22:233-240. Examines association between glucose levels and cardiovascular disease.
47. 47 Ko GTC, Chan JCN, Lau E, Woo J, Cockram CS: Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care 1997, 20:170-172.
48. 48 Temelkova-Kurktschiev TS, Koehler C, Leonhart W, et al.: Increased intimal-medial thickness in newly detected type 2 diabetes. Diabetes Care 1999, 22:333-338.
49. 49 Haffner SM: The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998, 19:583-553.
50. 50 Perry RC, Baron AD: Impaired glucose tolerance. Why is it not a disease? Diabetes Care 1999, 22:883-885.
51. 51 Engelgau MM, Aubert RE, Thompson TJ, Herman WH: Screening for NIDDM in nonpregnant adults. Diabetes Care 1995, 18:1606-1618.
52. 52 Knowler WC: Screening for NIDDM: opportunities for detection, treatment and prevention. Diabetes Care 1994, 17:445-450.
53. 53 Andersson DK, Lundbld E, Svardsudd K: A model of early diagnosis in type 2 diabetes mellitus in primary health care. Diabetic Med 1993, 10:167-173.
54. 54 CDC Diabetes Cost-Effectiveness Study Group: The cost-effectiveness of screening for type 2 diabetes. JAMA 1998, 280:1757-1763.
55. 55 Marwick C: Development of noninvasive methods to monitor blood glucose levels in people with diabetes. JAMA 1998, 280, 312-313.
56. 56 Harris MI: Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993, 16:642-652.
57. 57 The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999, 22:622-634.
58. 58 Henry RR: Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. AJM 1998, 105(Suppl A):205-265.